{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:52:29Z","timestamp":1788177149385,"version":"build-2803163510"},"reference-count":69,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder characterized by cardiac hypertrophy disproportionate to loading stimuli (e.g. hypertension or aortic stenosis). Diagnosing HCM requires a thorough examination of clinical symptoms, with echocardiography as the key initial imaging tool. Multimodality imaging further supports diagnosis, helps assess left ventricular outflow obstruction, and aids in risk stratification for sudden cardiac death. The cornerstone of HCM management remains pharmacological therapy with \u03b2-blockers and calcium channel blockers serving as first-line agents to alleviate symptoms and reduce left ventricular outflow tract obstruction. More recently, cardiac myosin inhibitors have revolutionized the treatment paradigm for obstructive HCM. Procedural interventions such as septal reduction therapy are reserved for refractory cases. Genetic testing and risk stratification for sudden cardiac death play a critical role in treatment decisions, guiding further testing in first-degree relatives and ICD implantation in high-risk individuals. Exercise recommendations have evolved based on recent data, challenging traditional restrictions and emphasizing individualized plans.<\/jats:p>","DOI":"10.15420\/usc.2023.21","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:32:22Z","timestamp":1728909142000},"source":"Crossref","is-referenced-by-count":10,"title":["Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures"],"prefix":"10.15420","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0820-4715","authenticated-orcid":false,"given":"Sukriti","family":"Banthiya","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ascension Providence Hospital\/Michigan State University College of Human Medicine, Southfield, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-6565","authenticated-orcid":false,"given":"Larissa","family":"Check","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-5088","authenticated-orcid":false,"given":"Jessica","family":"Atkins","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023;81:1835\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.393; PMID:\u00a037137593.","DOI":"10.1016\/j.jacc.2023.03.393"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res 2019;124:1598\u2013617. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.313572; PMID:\u00a031120821.","DOI":"10.1161\/circresaha.119.313572"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:749\u201370. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311059; PMID:\u00a028912181.","DOI":"10.1161\/circresaha.117.311059"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Gwathmey JK, Warren SE, Briggs GM, et al. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991;87:1023\u201331. https:\/\/doi.org\/10.1172\/JCI115061; PMID:\u00a01999483.","DOI":"10.1172\/jci115061"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018;379:655\u201368. https:\/\/doi.org\/10.1056\/NEJMra1710575; PMID:\u00a030110588.","DOI":"10.1056\/NEJMra1710575"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (\u201csmall vessel\u201d) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545\u201357. https:\/\/doi.org\/10.1016\/s0735-1097(86)80181-4; PMID:\u00a03745699.","DOI":"10.1016\/s0735-1097(86)80181-4"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Giannopoulos AA, Buechel RR, Kaufmann PA. Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies. J Nucl Cardiol 2023;30:800\u201310. https:\/\/doi.org\/10.1007\/s12350-022-03040-2; PMID:\u00a035915323.","DOI":"10.1007\/s12350-022-03040-2"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987\u201391. https:\/\/doi.org\/10.1161\/01.cir.96.9.2987; PMID:\u00a09386166.","DOI":"10.1161\/01.cir.96.9.2987"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Yoshida N, Ikeda H, Wada T, et al. Exercise-induced abnormal blood pressure responses are related to subendocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 1998;32:1938\u201342. https:\/\/doi.org\/10.1016\/s0735-1097(98)00498-7; PMID:\u00a09857875.","DOI":"10.1016\/s0735-1097(98)00498-7"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Braunwald E, Lambrew CT, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis: I. A description of the disease based upon an analysis of 64 patients. Circulation 1964;29(Suppl 4):3\u2013119. https:\/\/doi.org\/10.1161\/01.CIR.29.5S4.IV-3; PMID:\u00a014227306.","DOI":"10.1161\/01.cir.29.5s4.iv-3"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Kansal S, Roitman D, Sheffield LT. Interventricular septal thickness and left ventricular hypertrophy. An echocardiographic study. Circulation 1979;60:1058\u201365. https:\/\/doi.org\/10.1161\/01.CIR.60.5.1058; PMID:\u00a0158445.","DOI":"10.1161\/01.cir.60.5.1058"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Llamas-Esper\u00f3n GA, Llamas-Delgado G. Hypertrophic cardiomyopathy. Proposal for a new classification. Arch Cardiol Mex 2022;92:377\u201389. https:\/\/doi.org\/10.24875\/ACM.21000301; PMID:\u00a035772124.","DOI":"10.24875\/ACME.M22000342"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Austin BA, Kwon DH, Smedira NG, et al. Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009;22:105.e5\u20136. https:\/\/doi.org\/10.1016\/j.echo.2008.10.022; PMID:\u00a019131012.","DOI":"10.1016\/j.echo.2008.10.022"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Collier P, Phelan D, Klein A. A test in context: myocardial strain measured by speckle-tracking echocardiography. J Am Coll Cardiol 2017;69:1043\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.012; PMID:\u00a028231932.","DOI":"10.1016\/j.jacc.2016.12.012"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Tower-Rader A, Mohananey D, To A, et al. Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: a systematic review of existing literature. JACC Cardiovasc Imaging 2019;12:1930\u201342. https:\/\/doi.org\/10.1016\/j.jcmg.2018.07.016; PMID:\u00a030219395.","DOI":"10.1016\/j.jcmg.2018.07.016"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Lee HJ, Hyun-Jung HKK, Rhee TM, et al. Left atrial reservoir strain-based left ventricular diastolic function grading and incident heart failure in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2022;15:e013556. https:\/\/doi.org\/10.1161\/CIRCIMAGING.121.013556; PMID:\u00a035439039.","DOI":"10.1161\/circimaging.121.013556"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19:91\u20139. https:\/\/doi.org\/10.1016\/0735-1097(92)90057-T; PMID:\u00a01729351.","DOI":"10.1016\/0735-1097(92)90057-t"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa021332; PMID:\u00a012540642.","DOI":"10.1056\/nejmoa021332"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2017;10:1374\u201386. https:\/\/doi.org\/10.1016\/j.jcmg.2017.07.016; PMID:\u00a029122139.","DOI":"10.1016\/j.jcmg.2017.07.016"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;142:e558\u2013631. https:\/\/doi.org\/10.1161\/CIR.0000000000000937; PMID:\u00a033215931.","DOI":"10.1161\/CIR.0000000000000945"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ayoub C, Geske JB, Larsen CM, et al. Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy. Am J Cardiol 2017;120:2265\u201371. https:\/\/doi.org\/10.1016\/j.amjcard.2017.08.047; PMID:\u00a029054275.","DOI":"10.1016\/j.amjcard.2017.08.047"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.644682; PMID:\u00a017088454.","DOI":"10.1161\/circulationaha.106.644682"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Keskin B, Karag\u00f6z A, \u00c7i\u00e7ek MB, et al. Echocardiographic imaging of systolic anterior motion caused by extremely elongated posterior mitral leaflet in hypertrophic cardiomyopathy. Anatol J Cardiol 2019;21:289\u201391. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2019.04741; PMID:\u00a031062752.","DOI":"10.14744\/anatoljcardiol.2019.04741"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sherrid MV, Balaram S, Kim B, et al. The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context. J Am Coll Cardiol 2016;67:1846\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2016.01.071; PMID:\u00a027081025.","DOI":"10.1016\/j.jacc.2016.01.071"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000;36:1344\u201354. https:\/\/doi.org\/10.1016\/S0735-1097(00)00830-5; PMID:\u00a011028493.","DOI":"10.1016\/s0735-1097(00)00830-5"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Urbano-Moral JA, Gutierrez-Garcia-Moreno L, Rodriguez-Palomares JF, et al. Structural abnormalities in hypertrophic cardiomyopathy beyond left ventricular hypertrophy by multimodality imaging evaluation. Echocardiography 2019;36:1241\u201352. https:\/\/doi.org\/10.1111\/echo.14393; PMID:\u00a031162742.","DOI":"10.1111\/echo.14393"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699\u2013708. https:\/\/doi.org\/10.1016\/0735-1097(95)00390-8; PMID:\u00a07594106.","DOI":"10.1016\/0735-1097(95)00390-8"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Shah PM, Taylor RD, Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve. Am J Cardiol 1981;48:258\u201362. https:\/\/doi.org\/10.1016\/0002-9149(81)90605-6; PMID:\u00a07196686.","DOI":"10.1016\/0002-9149(81)90605-6"},{"key":"ref28","unstructured":"Neubauer S, Kolm P, Ho CY, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll Cardiol 2019;74:2333\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1057; PMID:\u00a031699273."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Yu EHC, Omran AS, Douglas Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000;36:2219\u201325. https:\/\/doi.org\/10.1016\/S0735-1097(00)01019-6; PMID:\u00a011127464.","DOI":"10.1016\/s0735-1097(00)01019-6"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Guigui SA, Torres C, Escolar E, Mihos CG. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review. J Thorac Dis 2022;14:2309\u201325. https:\/\/doi.org\/10.21037\/jtd-22-182; PMID:\u00a035813751.","DOI":"10.21037\/jtd-22-182"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Nampiaparampil RG, Swistel DG, Schlame M, et al. Intraoperative two- and three-dimensional transesophageal echocardiography in combined myectomy-mitral operations for hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2018;31:275\u201388. https:\/\/doi.org\/10.1016\/j.echo.2017.11.016; PMID:\u00a029502589.","DOI":"10.1016\/j.echo.2017.11.016"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Ommen SR, Park SH, Click RL, et al. Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. Am J Cardiol 2002;90:1022\u201324. https:\/\/doi.org\/10.1016\/S0002-9149(02)02694-2; PMID:\u00a012398979.","DOI":"10.1016\/s0002-9149(02)02694-2"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives. JACC Cardiovasc Imaging 2020;13:283\u201396. https:\/\/doi.org\/10.1016\/j.jcmg.2019.02.031; PMID:\u00a031202753.","DOI":"10.1016\/j.jcmg.2019.02.031"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Caselli S, Maron MS, Urbano-Moral JA, et al. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol 2014;114:1383\u201389. https:\/\/doi.org\/10.1016\/j.amjcard.2014.07.070; PMID:\u00a025217454.","DOI":"10.1016\/j.amjcard.2014.07.070"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186\u201393. https:\/\/doi.org\/10.1161\/01.CIR.0000152819.97857.9D; PMID:\u00a015630027.","DOI":"10.1161\/01.CIR.0000152819.97857.9D"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Mordi IR, Singh S, Rudd A, et al. Comprehensive echocardiographic and cardiac magnetic resonance evaluation differentiates among heart failure with preserved ejection fraction patients, hypertensive patients, and healthy control subjects. JACC Cardiovasc Imaging 2018;11:577\u201385. https:\/\/doi.org\/10.1016\/j.jcmg.2017.05.022; PMID:\u00a028823736.","DOI":"10.1016\/j.jcmg.2017.05.022"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Moon JCC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151\u20135. https:\/\/doi.org\/10.1016\/j.ehj.2003.09.017; PMID:\u00a014643276.","DOI":"10.1016\/j.ehj.2003.09.017"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Rowin EJ, Maron MS. The role of cardiac MRI in the diagnosis and risk stratification of hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 2016;5:197\u2013202. https:\/\/doi.org\/10.15420\/aer.2016:13:3; PMID:\u00a028116085.","DOI":"10.15420\/aer.2016:13:3"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033\u201341. https:\/\/doi.org\/10.1161\/01.CIR.0000162460.36735.71; PMID:\u00a015824202.","DOI":"10.1161\/01.cir.0000162460.36735.71"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Lasam G. Brockenbrough-Braunwald-Morrow sign: an evaluative hemodynamic maneuver for left ventricular outflow tract obstruction. Cardiol Res 2018;9:180\u201382. https:\/\/doi.org\/10.14740\/cr676w; PMID:\u00a029904456.","DOI":"10.14740\/cr676w"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Kumar S, Van Ness G, Bender A, et al. Standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2018;31:791\u201398. https:\/\/doi.org\/10.1016\/j.echo.2018.01.022; PMID:\u00a029573929.","DOI":"10.1016\/j.echo.2018.01.022"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Gilligan DM, Nihoyannopoulos P, Fletcher A, et al. Symptoms of hypertrophic cardiomyopathy, with special emphasis on syncope and postprandial exacerbation of symptoms. Clin Cardiol 1996;19:371\u201378. https:\/\/doi.org\/10.1002\/clc.4960190509; PMID:\u00a08723595.","DOI":"10.1002\/clc.4960190509"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Paz R, Jortner R, Tunick PA, et al. The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy. N Engl J Med\u00a01996;335:938\u201341. https:\/\/doi.org\/10.1056\/NEJM199609263351305; PMID:\u00a08782501.","DOI":"10.1056\/nejm199609263351305"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:1864\u201369. https:\/\/doi.org\/10.1016\/S0735-1097(02)02495-6; PMID:\u00a012446072.","DOI":"10.1016\/S0735-1097(02)02495-6"},{"key":"ref45","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2024;149:e1239\u2013311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250; PMID:\u00a038718139."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Ho CY, Day SM, Axelsson Aa, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.  Nat Med 2021;27:1818\u201324. https:\/\/doi.org\/10.1038\/s41591-021-01505-4; PMID:\u00a034556856.","DOI":"10.1038\/s41591-021-01505-4"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Spoladore R, Maron MS, D\u2019Amato R, et al. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 2012;33:1724\u201333. https:\/\/doi.org\/10.1093\/eurheartj\/ehs150; PMID:\u00a022719025.","DOI":"10.1093\/eurheartj\/ehs150"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.012; PMID:\u00a015837258.","DOI":"10.1016\/j.jacc.2005.01.012"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Zampieri M, Berteotti M, Ferrantini C, et al. Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives. Curr Heart Fail Rep 2021;18:169\u201379. https:\/\/doi.org\/10.1007\/s11897-021-00523-0; PMID:\u00a034148184.","DOI":"10.1007\/s11897-021-00523-0"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Masri A, Lester SJ, Stendahl J, et al. Long-term safety and efficacy of mavacamten in patients (PTS) with symptomatic obstructive hypertrophic cardiomyopathy (HCM): updated results from the PIONEER-OLE study. J Am Coll Cardiol 2023;81 Suppl:346. https:\/\/doi.org\/10.1016\/S0735-1097(23)00790-8.","DOI":"10.1016\/s0735-1097(23)00790-8"},{"key":"ref51","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;396:759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X; PMID:\u00a032871100."},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 2022;80:95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048; PMID:\u00a035798455.","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Desai MY, Owens A, Geske JB, et al. Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks. Circulation 2023;147:850\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062534; PMID:\u00a036335531.","DOI":"10.1161\/circulationaha.122.062534"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2023;81:34\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.020; PMID:\u00a036599608.","DOI":"10.1016\/j.jacc.2022.10.020"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Subramanian M, Sravani Vucha, Krishna SP, et al. Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2023;188:80\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.054; PMID:\u00a036473308.","DOI":"10.1016\/j.amjcard.2022.10.054"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761\u201396. https:\/\/doi.org\/10.1161\/CIR.0b013e318223e230; PMID:\u00a022068435.","DOI":"10.1161\/cir.0b013e318223e230"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(95)91267-3; PMID:\u00a07616800.","DOI":"10.1016\/s0140-6736(95)91267-3"},{"key":"ref58","unstructured":"Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2005.02.090; PMID:\u00a016053960."},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014. Circulation 2014;130:1617\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.011580; PMID:\u00a025462821.","DOI":"10.1161\/circulationaha.114.011580"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Maron BJ, Dearani JA, Smedira NG, et al. Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC Expert Panel. Am J Cardiol 2022;180:124\u201339. https:\/\/doi.org\/10.1016\/j.amjcard.2022.06.007; PMID:\u00a035965115.","DOI":"10.1016\/j.amjcard.2022.06.007"},{"key":"ref61","unstructured":"Long A, Mahoney P. Use of MitraClip to target obstructive SAM in severe diffuse-type hypertrophic cardiomyopathy: case report and review of literature. J Invasive Cardiol 2020;32:e228\u201332. PMID:\u00a032865508."},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Greaves SC, Roche AH, Neutze JM, et al. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J 1987;58:259\u201366. https:\/\/doi.org\/10.1136\/hrt.58.3.259; PMID:\u00a03663427.","DOI":"10.1136\/hrt.58.3.259"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227\u201332. https:\/\/doi.org\/10.1161\/01.CIR.0000066323.15244.54; PMID:\u00a012707239.","DOI":"10.1161\/01.cir.0000066323.15244.54"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823\u201331. https:\/\/doi.org\/10.1056\/NEJM200106143442403.","DOI":"10.1056\/nejm200106143442403"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol 1997;29:549\u201355. https:\/\/doi.org\/10.1016\/S0735-1097(96)00530-X; PMID:\u00a09060892.","DOI":"10.1016\/S0735-1097(96)00530-X"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Weissler-Snir A, Allan K, Cunningham K, et al. Hypertrophic cardiomyopathy-related sudden cardiac death in young people in Ontario. Circulation 2019;140:1706\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040271; PMID:\u00a031630535.","DOI":"10.1161\/circulationaha.119.040271"},{"key":"ref67","unstructured":"Noureldin RA, Liu S, Nacif MS, et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:17. https:\/\/doi.org\/10.1186\/1532-429X-14-17; PMID:\u00a022348519."},{"key":"ref68","unstructured":"Lampert R, Ackerman MJ, Marino BS, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiol 2023;8:595\u2013605. https:\/\/doi.org\/10.1001\/jamacardio.2023.1042; PMID:\u00a037195701."}],"container-title":["US Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2023.21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:32:37Z","timestamp":1728909157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2023.21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":69,"URL":"https:\/\/doi.org\/10.15420\/usc.2023.21","relation":{},"ISSN":["1758-390X","1758-3896"],"issn-type":[{"value":"1758-390X","type":"electronic"},{"value":"1758-3896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"article-number":"e17"}}